| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5926676 | American Heart Journal | 2016 | 8 Pages |
Abstract
There is clinical equipoise on the issue of optimal platelet inhibition after CABG. The TiCAB trial will provide a pivotal comparison of the efficacy and safety of ticagrelor compared with ASA after CABG.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Antoinette MD, Sigrid MD, Moritz MD, Andreas MD, Katharina MD, Dieter MD, Rainer MD, Bernhard C. MD, Friedrich A. MD, Gerold MD, Theodor MD, Michael MD, Martin MD, Rainer MD, Thomas MD, Tibor MD, Christoph MD, Felix MD, Heribert MD,